"Gangliosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)
| Descriptor ID |
D005732
|
| MeSH Number(s) |
D09.400.410.420.025.475 D10.390.470.025.475 D10.570.877.360.025.475
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gangliosides".
Below are MeSH descriptors whose meaning is more specific than "Gangliosides".
This graph shows the total number of publications written about "Gangliosides" by people in this website by year, and whether "Gangliosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 1 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gangliosides" by people in Profiles.
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
-
Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. Br J Cancer. 2022 03; 126(4):615-627.
-
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann N Y Acad Sci. 2022 02; 1508(1):35-53.
-
Correcting for sparsity and interdependence in glycomics by accounting for glycan biosynthesis. Nat Commun. 2021 08 17; 12(1):4988.
-
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 03; 9(3).
-
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Mol Oncol. 2020 08; 14(8):1760-1778.
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
-
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019 04; 41(3):163-169.
-
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Clin Cancer Res. 2019 05 01; 25(9):2915-2924.
-
The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Opin Drug Saf. 2018 Dec; 17(12):1257-1262.